◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: quick Peptide · Injectable SKIP-FOR-NOW LOW

Cerluten

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW LOW

Mechanism precision is very thin, evidence is thin Russian-only with zero Western replication, and the broader Khavinson short-peptide framework itself is contested — many cleaner liver-protection options (NAC, milk thistle, choline) cover the same use case with stronger evidence.

Research pass: quick
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload (this-archetype)
    SKIP

    Liver protection not a stated priority; if it were, NAC (already in Canonical stack) covers it.

  • 30-50, executive maintenance
    SKIP

    Use NAC + milk thistle + choline + reduce alcohol. Vastly more evidence, vastly cheaper.

  • 50+, mild cognitive decline
    SKIP

    for liver use case; if exploring full Khavinson stack as a curiosity, epithalon has marginally more data.

  • Anxiety-prone
    N
  • High athletic load, tested status
    SKIP

    WADA status unclear for unscheduled gray-market peptide; better-evidenced options exist.

  • Sleep-disordered
    N
  • Recovery-focused (post-injury, post-illness)
    SKIP

    NAC, glycine, glutathione precursors are better evidenced.

  • Strength/anabolic-focused
    N
▸ Subjective experience (deep)

Mostly silent — users do not report acute felt effects (consistent with most Khavinson peptides, which are pitched as long-arc gerontological tools rather than acute nootropics or felt-effect compounds). Some users report mild GI calm.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown / not characterized
  • Recommended cycle: Khavinson group recommends 30-day courses 2-3×/year
  • Reset protocol if needed: N/A
▸ Stacking deep dive

Synergistic with

  • N/A — no credible interaction data.

Avoid stacking with

  • N/A — no credible interaction data.

Neutral / safe co-administration

  • Presumed safe with most things given short peptide nature, but this is a mechanistic guess, not a data-backed claim.
▸ Drug interactions deep dive

None characterized in Western literature. CYP interactions unknown.

▸ Pharmacogenomics

None characterized.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market import RUPharma ~$30-50/30 caps Medium Khavinson-line peptides; standard gray-market shipping
Gray-market import CosmicNootropic ~$35-55/30 caps Medium Same product line, alternate vendor
▸ Biomarkers to track (deep)
  • Baseline (before starting): ALT, AST, GGT, bilirubin, albumin (standard liver panel).
  • During use: Repeat liver panel mid-cycle and post-cycle if running anyway.
  • Post-cycle (if cycled): Liver panel at 30 days post.
▸ Controversies / open debates Live debate
  • Core controversy: The entire Khavinson short-peptide framework is contested. Western pharmacology has not validated the "tissue-specific oral peptide reaches nucleus" mechanism for any member of the family. Independent replication outside the Khavinson group is essentially zero.
  • What would change the verdict: A Western-indexed RCT showing meaningful liver-marker improvements vs. placebo, OR a published amino-acid sequence with mechanistic data showing how the peptide reaches hepatocyte nuclei after oral administration.
  • Steel-man: Russian gerontology literature has a different evidence culture; some Khavinson compounds (cortexin in particular) do have somewhat more clinical use behind them. Cerluten specifically is not in that better-evidenced subset.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW LOW. Thin Russian-only evidence, contested framework, cleaner alternatives exist (NAC, milk thistle, choline) with vastly stronger evidence for the same use case.
▸ Open questions / gaps Open
  • No published amino-acid sequence Western-indexed
  • No bioavailability data
  • No pharmacokinetic data
  • No independent replication
  • No comparative data vs. NAC / silymarin / phosphatidylcholine

References

Khavinson VKh. "Peptides and Ageing." Neuro Endocrinol Lett 2002;23 Suppl 3:11-144. **PMID: 12374906**

pubmed.ncbi.nlm.nih.gov · 2002

Foundational Khavinson framework paper covering the broad short-peptide bioregulator hypothesis under which Cerluten is positioned. Background reference; does not establish Cerluten-specific efficacy.

View Study

Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology 2010;11(2):139-149. **PMID: 19830585**

pubmed.ncbi.nlm.nih.gov · 2010

Khavinson group review of peptide bioregulator long-term geroprotective effects; broad framework support, no Cerluten-specific RCT data.

View Study

Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. "Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line." Int J Mol Sci 2022;23(7):3552. **PMID: 35408914**

pubmed.ncbi.nlm.nih.gov · 2022

In vitro mechanism work on Khavinson short peptides; broad family-level support, no Cerluten-specific in vivo translation.

View Study

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…